Inactief instrument

Andere talen ImmunoCellular Therapeutics Ltd Nyse

Aandelen

US4525362046

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613	07/11
EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil	06-09-23
EOM Pharmaceutical Holdings Announces Topline Results of Its Covid-19 Clinical Trial of Eom613 in Brazil	06-09-23
EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million.	02-08-23
EOM Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	20-12-22
ImmunoCellular Therapeutics Ltd. has Changed its Name to EOM Pharmaceuticals Holdings, Inc	10-11-22
EOM Pharmaceuticals Holdings, Inc. announced that it has received $0.75 million in funding	12-09-22
EOM Pharmaceuticals Holdings, Inc. announced a financing transaction	26-08-22
EOM Pharmaceuticals Holdings, Inc. has filed an IPO in the amount of $25 million.	24-06-22
ImmunoCellular Therapeutics, Ltd. Auditor Raises 'Going Concern' Doubt	24-06-22
ImmunoCellular Therapeutics, Ltd. Auditor Raises 'Going Concern' Doubt	10-02-22
EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement	02-12-21
EOM Pharmaceuticals, Inc. acquired ImmunoCellular Therapeutics, Ltd. in a reverse merger transaction.	02-12-21
ImmunoCellular Therapeutics : Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market	28-06-21
ImmunoCellular Therapeutics, Ltd.(AMEX:IMUC) dropped from S&P TMI Index	18-10-18
ImmunoCellular Therapeutics, Ltd. Announces Executive Changes, Effective October 15, 2018	15-10-18
ImmunoCellular Therapeutics, Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	16-08-18
ImmunoCellular Therapeutics Is Considering Strategic Alternatives	13-08-18
ImmunoCellular Therapeutics, Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018	14-05-18
ImmunoCellular Therapeutics, Ltd. Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program	12-04-18

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen ImmunoCellular Therapeutics Ltd Nyse

Aandelen

US4525362046

Andere talen

Filters